Appropriate selection of patients for 1st line monotherapy in advanced or unresectable HCC and treatment management in relation with AEs

  • calender Tuesday, 23rd November, 2021
  • clock 17:00h - 18:30h (UTC)

Richard S Finn, MD

Richard S Finn, MD
Gastrointestinal Medical Oncologist

Geffen School of Medicine at UCLA in the Department of Medicine Division of Hematology/Oncology, USA

United States
More information

Mohamed Bouattour, MD

Mohamed Bouattour, MD
Gastroenterologist, Hepatologist and Medical Oncologist

The University Beaujon Hospital Clichy, Beaujon, France

France
More information

James J. Harding, MD

James J. Harding, MD
Gastrointestinal Oncologist

Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, USA

United States
More information

The HCC Virtual Experts Knowledge share will address “Appropriate selection of patients for 1st line monotherapy in advanced or unresectable HCC and treatment management in relation with AEs”. Chaired by Prof. Richard Finn, MD, (USA) and co-chaired by Dr Mohamed Bouattour (France) and James Harding, MD (USA).

The educational objectives for the meeting are:

  • Explore the patient-profile who could benefit from VEGFR-TKI monotherapy 1st line in advanced or unresectable HCC
  • Interpret the real-world data and understand the implications for clinical practice
  • Understand the safety profile of the monotherapies, be able to recognise the cause of toxicities and know the appropriate dosing strategies to manage side effects
  • A look into the future, the potential of combination therapies in the treatment of HCC
endorsement

This HCC CONNECT programme is supported by Independent Educational Grant from Eisai Europe Limited.